Dr. Kapil Dhingra is Managing Member, KAPital Consulting LLC, a healthcare consulting firm that he founded in 2008 to provide oncology-related strategic consulting for novel diagnostics and therapeutics. Dr. Dhingra received his MBBBS degree from the All India Institute of Medical Sciences, New Delhi, India. He completed Internal Medicine residency at Lincoln Hospital in New York followed by Hematology-Oncology fellowship at Emory University, Atlanta. From 1989-1996, he was an academic faculty member at MD Anderson Cancer Center in Texas where he pursued translational laboratory research and clinical research. His laboratory research focused on detection of minimal residual disease in CML and on study of early molecular alterations in breast cancer. His clinical trials largely focused on the emerging field of biological therapy. He joined Eli Lilly and company in Indianapolis in 1996 where he directed the clinical development of SERMs and hormonal therapy drugs for prostate cancer. From 1999-2008, he worked at Roche oncology where he played a leadership role in the development of a number of important cancer drugs, including Herceptin, Rituxan, Tarceva, Avastin, and, Zelboraf. He was Vice President and Head, Oncology Clinical Development from 2002-2008. Throughout his industry career, he maintained a faculty appointment, initially at Indiana University School of Medicine and, subsequently, at Memorial Sloan-Kettering Cancer Center, New York. He has authored or co-authored more than 100 publications and abstracts. He was a member of the Board of Directors of SARC consortium from 2009-2013. He currently serves on the NCI Experimental Therapeutics Special Emphasis panel, International Scientific Advisory Board of Institut Gustave Roussy, and, on the Product Development Review Committee of Cancer Prevention and Research Institute of Texas.

 Oncology